2023
Treatment options for necrobiosis lipoidica: a systematic review
Nihal A, Caplan A, Rosenbach M, Damsky W, Mangold A, Shields B. Treatment options for necrobiosis lipoidica: a systematic review. International Journal Of Dermatology 2023, 62: 1529-1537. PMID: 37772666, DOI: 10.1111/ijd.16856.Peer-Reviewed Original ResearchConceptsTopical calcineurin inhibitorsNecrobiosis lipoidicaTopical corticosteroidsCalcineurin inhibitorsTreatment optionsCase reportJAK inhibitorsSystematic reviewTreatment of NLLimited high-quality evidenceHigh-quality evidenceHigh morbidityCombination therapyRecalcitrant diseaseTreatment modalitiesCompression therapyStandardized endpointsTherapeutic modalitiesClinical careCollagen degenerationTreatment efficacyNew treatmentsLiterature searchTherapyCorticosteroidsMolecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis
Hwang E, Abdelghaffar M, Shields B, Damsky W. Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis. JID Innovations 2023, 3: 100220. PMID: 37719661, PMCID: PMC10500476, DOI: 10.1016/j.xjidi.2023.100220.Peer-Reviewed Original ResearchDisease pathogenesisCutaneous granulomatous disordersLow-quality evidenceRepository corticotropin injectionOutcome of treatmentImmunomodulatory medicationsPulmonary sarcoidosisCutaneous sarcoidosisGranulomatous disorderNecrobiosis lipoidicaCorticotropin injectionMacrophage accumulationGranuloma annulareGranulomatous diseaseCutaneous granulomatous diseasesTargeted therapyDrug AdministrationMolecular pathogenesisNew treatmentsSystematic reviewPathogenesisTherapyDistinct diseasesTherapeutic innovationsDiseaseAssessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology
Mortlock R, Ma E, Cohen J, Damsky W. Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology. Journal Of Investigative Dermatology 2023, 143: 1412-1422. PMID: 37341663, PMCID: PMC10830170, DOI: 10.1016/j.jid.2023.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAtopic dermatitisSkin diseasesInflammatory skin diseaseInflammatory skin conditionImmunologic biomarkersImmune biomarkersPersonalized medicineInflammatory dermatosesImmunologic approachesTherapy selectionSkin conditionsSingle-cell RNA sequencingMolecular profilingBiomarkersTissue stainingPsoriasisDermatitisDiseaseDermatologyRNA sequencingMedicineCurettageDermatosesTherapyPersonalized classificationImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearance
2022
Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression
Ahmad M, Murphy M, Damsky W, Leventhal J. Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. International Journal Of Dermatology 2022, 62: e424-e426. PMID: 36468831, DOI: 10.1111/ijd.16538.Peer-Reviewed Original ResearchPatient perspectives on the lived experience of granuloma annulare
Clark A, Murphy M, King B, Cohen J, Rosenbach M, Barbieri J, Damsky W. Patient perspectives on the lived experience of granuloma annulare. British Journal Of Dermatology 2022, 188: 134-136. PMID: 36689498, DOI: 10.1093/bjd/ljac004.Peer-Reviewed Original Research
2016
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell & Melanoma Research 2016, 29: 590-597. PMID: 27287723, PMCID: PMC5331933, DOI: 10.1111/pcmr.12498.Peer-Reviewed Original ResearchConceptsMouse melanoma cell lineMelanoma cell linesCell linesMouse cancer cell linesVariety of cancersCancer cell linesMouse melanoma linesImmune therapyTumor immunologyCancer immunologyHost miceMouse modelCancer modelMelanoma linesDriver mutationsGenetic alterationsCancer biologyImmunologyTherapyCancerMiceA comprehensive system of congenic mouse melanoma models for evaluation of immune therapies
Bosenberg M, Meeth K, Damsky W. A comprehensive system of congenic mouse melanoma models for evaluation of immune therapies. The Journal Of Immunology 2016, 196: 144.19-144.19. DOI: 10.4049/jimmunol.196.supp.144.19.Peer-Reviewed Original ResearchImmune therapyMouse modelImmune systemImmune checkpoint inhibitorsSubset of patientsRenal cell carcinomaMouse melanoma modelMouse melanoma cell lineCheckpoint inhibitorsMelanoma cell linesMelanoma patientsCell carcinomaLung cancerCancer immunologyMalignant melanomaProstate cancerTherapeutic approachesMelanoma modelSkin cancerHuman melanomaTherapyTumor microenvironmentCancerFlow cytometryPatients